2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
4
Breast Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Mesothelioma, Malignant
2
Melanoma
2
Carcinoma
2
Adult Solid Neoplasm
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumor, Pleural
1
Solid Neoplasm
1
Seminoma
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteolysis
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Malignant Solid Tumour
1
Liver Neoplasms
1
Hypercalcemia
1
Interventions
Cisplatin
7
Etoposide
6
pembrolizumab
4
Topotecan
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
belinostat
2
Temozolomide
2
RRx-001
2
Paclitaxel
2
vosaroxin
1
vinflunine
1
veliparib
1
taxane
1
sagopilone
1
sacituzumab govitecan
1
pomalidomide
1
lurtotecan
1
liposomal doxorubicin
1
etoposide phosphate
1
enzalutamide
1
bemiparin
1
belotecan
1
atezolizumab
1
apalutamide
1
alvocidib
1
abiraterone
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
ARQ 197
×
Clear all
NCT02608411
2023-10-13
TIMES
Istituto Oncologico Veneto IRCCS
Phase 2
Terminated
5 enrolled